Clinics in Dermatology
Volume 24, Issue 6 , Pages 498-508 , November 2006

Metabolic diseases: gout

References 

  1. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143:499–516
  2. Choi HK, Curhan G. Gout: epidemiology and lifestyle choices. Curr Opin Rheumatol. 2005;17:341–345
  3. Nriagu JO. Saturnine gout among Roman aristocrats. Did lead poisoning contribute to the fall of the Empire?. N Engl J Med. 1983;308:660–663
  4. Healey LA. Port wine and the gout. Arthritis Rheum. 1975;18:659–662
  5. Steinbock RT. Lead ingestion in history. N Engl J Med. 1979;301:277
  6. Weilerstein R. Diuretics and hyperuricemia. N Engl J Med. 1970;283:1170
  7. Sfikakis P. Diuretics and hyperuricemia. N Engl J Med. 1970;282:1047–1048
  8. Shibolet O, Elinav E, Ilan Y, et al. Reduced incidence of hyperuricemia, gout, and renal failure following liver transplantation in comparison to heart transplantation: a long-term follow-up study. Transplantation. 2004;77:1576–1580
  9. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43:103–108
  10. Enomoto AKH, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417:447–452
  11. Jantzen PT, Connor KE, DiCarlo G, et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide–releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 2002;22:2246–2254
  12. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421–426
  13. Marinello E, Riario-Sforza G, Marcolongo R. Plasma follicle-stimulating hormone, luteinizing hormone, and sex hormones in patients with gout. Arthritis Rheum. 1985;28:127–131
  14. Rosen R, Tomer Y, Carel R, et al. Serum 17-beta-estradiol and testosterone levels in asymptomatic hyperuricaemic men. Clin Rheumatol. 1994;13:219–223
  15. Takahashi S, Yamamoto T, Moriwaki Y, et al. Impaired lipoprotein metabolism in patients with primary gout—influence of alcohol intake and body weight. Br J Rheumatol. 1994;33:731–734
  16. Wortmann RL, Kelley WN. Chapter 87: gout and hyperuricemia. In:  Harris ED editors. Kelley's textbook of rheumatology. 7th ed.. Philadelphia: Elsevier Science; 2005;p. 1402–1429
  17. Kahn HS, Valdez R. Metabolic risks identified by the combination of enlarged waist and elevated triacylglycerol concentration. Am J Clin Nutr. 2003;78:928–934
  18. Tuomilehto J, Zimmet P, Wolf E, et al. Plasma uric acid level and its association with diabetes mellitus and some biologic parameters in a biracial population of Fiji. Am J Epidemiol. 1988;127:321–336
  19. Huth K, Burkard M, Goebel T. Dyslipoproteinemia and diabetes mellitus in a metabolic syndrome. Fortschr Med. 1992;110:200–204
  20. Terkeltaub RA. Chapter 113: pathogenesis and treatment of crystal-induced inflammation. In:  Koopman WJM,  Larry W editor. 15th ed.. Arthritis & Allied Conditions. 2303:Philadelphia: Lippincott Williams & Wilkins; 2005;p. 39
  21. Choi HK. Diet, alcohol, and gout: how do we advise patients given recent developments?. Curr Rheumatol Rep. 2005;7:220–226
  22. Torralba TP, Bayani-Sioson PS. The Filipino and gout. Semin Arthritis Rheum. 1975;4:307–320
  23. Baumann RR, Jillson OF. Hyperuricemia and psoriasis. J Invest Dermatol. 1961;36:105–107
  24. Bosmansky K, Trnavsky K. Psoriasis and gout: report of 4 cases. Clin Rheumatol. 1983;2:423–426
  25. Yu T, Weinreb N, Wittman R, et al. Secondary gout associated with chronic myeloproliferative disorders. Semin Arthritis Rheum. 1976;5:247–256
  26. Pochedly C. Hyperuricemia in leukemia and lymphoma. I. Clinical findings and pathophysiology. N Y State J Med. 1973;73:1085–1092
  27. Tsimberidou AM, Keating MJ. Hyperuricemic syndromes in cancer patients. Contrib Nephrol. 2005;147:47–60
  28. Craig MH, Poole GV, Hauser CJ. Postsurgical gout. Am Surg. 1995;61:56–59
  29. Moreau D. Pharmacological treatment of acute renal failure in intensive care unit patients. Contrib Nephrol. 2005;147:161–173
  30. Eckes L. The simultaneous occurrence of psoriasis, sarcoidosis and gout. Report of 3 cases. Hautarzt. 1975;26:357–361
  31. Kurtzman NA. Coexistent sarcoidosis and gout. J Lancet. 1965;85:195–196
  32. Chetrick A. Coexistent sarcoidosis, erythema nodosum, and gout. JAMA. 1963;186:950–952
  33. Poor G, Mituszova M. Saturnine gout. Baillieres Clin Rheumatol. 1989;3:51–61
  34. Rubin MR, Silverberg SJ. Rheumatic manifestations of primary hyperparathyroidism and parathyroid hormone therapy. Curr Rheumatol Rep. 2002;4:179–185
  35. Kang HC, Chung da E, Kim DW, et al. Early- and late-onset complications of the ketogenic diet for intractable epilepsy. Epilepsia. 2004;45:1116–1123
  36. Cameron JS, Simmonds HA. Hereditary hyperuricemia and renal disease. Semin Nephrol. 2005;25:9–18
  37. Malaga S, Pardo R, Malaga I, et al. Renal involvement in Down syndrome. Pediatr Nephrol. 2005;20:614–617
  38. Nyhan WL. Lesch-Nyhan disease. J Hist Neurosci. 2005';14:1–10
  39. Nyhan WL. Inherited hyperuricemic disorders. Contrib Nephrol. 2005;147:22–34
  40. Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290:F625–F631
  41. Noordzij TC, Leunissen KM, Van Hooff JP. Renal handling of urate and the incidence of gouty arthritis during cyclosporine and diuretic use. Transplantation. 1991;52:64–67
  42. Thiele RG, Schlesinger N. Ultrasonography is a reliable, non-invasive method for diagnosing gout. In: American College of Rheumatology Annual Scientific Meeting. San Diego, California: Wiley Interscience. 2005;[Abstr. 809]
  43. Wright S, Filippucci E, McVeigh C, et al. Characteristic features of gout: a sonographic study. In: American College of Rheumatology Annual Scientific Meeting. San Diego, CA: Wiley Interscience. 2005;[Abstr. 201]
  44. Terkeltaub RA, Ginsberg MH. The inflammatory reaction to crystals. Rheum Dis Clin North Am. 1988;14:353–364
  45. Suttenfield FD. Arthritis after intrasynovial injection of sodium urate crystals. Lancet. 1962;2:1380–1381
  46. Liu-Bryan R, Scott P, Sydlaske A, et al. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2005;52:2936–2946
  47. Dalbeth N, Haskard DO. Inflammation and tissue damage in crystal deposition diseases. Curr Opin Rheumatol. 2005;17:314–318
  48. Yagnik DR, Evans BJ, Florey O, et al. Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum. 2004;50:2273–2280
  49. Alvarez-Nemegyei J, Medina-Escobedo M, Villanueva-Jorge S, et al. Prevalence and risk factors for urolithiasis in primary gout: is a reappraisal needed?. J Rheumatol. 2005;32:2189–2191
  50. Kramer HJ, Choi HK, Atkinson K, et al. The association between gout and nephrolithiasis in men: The Health Professionals' Follow-up Study. Kidney Int. 2003;64:1022–1026
  51. Sorensen CM, Chandhoke PS. Hyperuricosuric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31:915–925
  52. Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol. 2002;168:1307–1314
  53. Gerster JC, Landry M, Dufresne L, et al. Imaging of tophaceous gout: computed tomography provides specific images compared with magnetic resonance imaging and ultrasonography. Ann Rheum Dis. 2002;61:52–54
  54. Aslam N, Lo S, McNab I. Gouty flexor tenosynovitis mimicking infection: a case report emphasising the value of ultrasound in diagnosis. Acta Orthop Belg. 2004;70:368–370
  55. Rousseau I, Cardinal EE, Raymond-Tremblay D, et al. Gout: radiographic findings mimicking infection. Skeletal Radiol. 2001;30:565–569
  56. Louis DS, Jebson PJ. Mimickers of hand infections. Hand Clin. 1998;14:519–529
  57. Kostman JR, Rush P, Reginato AJ. Granulomatous tophaceous gout mimicking tuberculous tenosynovitis: report of two cases. Clin Infect Dis. 1995;21:217–219
  58. Grassi W, Filippucci E, Farina A, et al. Sonographic imaging of the distal phalanx. Semin Arthritis Rheum. 2000;29:379–384
  59. ter Borg EJ, Rasker JJ. Gout in the elderly, a separate entity?. Ann Rheum Dis. 1987;46:72–76
  60. O'Dell JR. Gout in Heberden's nodes. Arthritis Rheum. 1983;26:1413–1414
  61. Simkin PA, Campbell PM, Larson EB. Gout in Heberden's nodes. Arthritis Rheum. 1983;26:94–97
  62. Wernick R, Winkler C, Campbell S. Tophi as the initial manifestation of gout. Report of six cases and review of the literature. Arch Intern Med. 1992;152:873–876
  63. Lagoutaris ED, Adams HB, DiDomenico LA, et al. Longitudinal tears of both peroneal tendons associated with tophaceous gouty infiltration. A case report. J Foot Ankle Surg. 2005;44:222–224
  64. Hung JY, Wang SJ, Wu SS. Spontaneous rupture of extensor pollicis longus tendon with tophaceous gout infiltration. Arch Orthop Trauma Surg. 2005;125:281–284
  65. Bond JR, Sim FH, Sundaram M. Radiologic case study. Gouty tophus involving the distal quadriceps tendon. Orthopedics. 2004;27(18):90–92
  66. Tan G, Chew W, Lai CH. Carpal tunnel syndrome due to gouty infiltration of the lumbrical muscles and flexor tendons. Hand Surg. 2003;8:121–125
  67. Weniger FG, Davison SP, Risin M, et al. Gouty flexor tenosynovitis of the digits: report of three cases. J Hand Surg [Am]. 2003;28:669–672
  68. Schuind FA, Clermont D, Stallenberg B, et al. Gouty involvement of flexor tendons. Chir Main. 2003;22:46–50
  69. Wurapa RK, Zelouf DS. Flexor tendon rupture caused by gout: a case report. J Hand Surg [Am]. 2002;27:591–593
  70. Gentili A. Advanced imaging of gout. Semin Musculoskelet Radiol. 2003;7:165–174
  71. Bastani B, Vemuri R, Gennis M. Acute gouty sacroiliitis: a case report and review of the literature. Mt Sinai J Med. 1997;64:383–385
  72. Gniadecka M, Wulf HC, Johansson CK, et al. Cutaneous tophi and calcinosis diagnosed in vivo by Raman spectroscopy. Br J Dermatol. 2001;145:672–674
  73. Snider AA, Barsky S. Gouty panniculitis: a case report and review of the literature. Cutis. 2005;76:54–56
  74. Conejo-Mir J, Pulpillo A, Corbi MR, et al. Panniculitis and ulcers in a young man. Arch Dermatol 1998; 134: 501, 4.
  75. Vorob'eva GP, Generalova S, Balkarov IM, et al. Panniculitis in gout. Ter Arkh. 1992;64:104–105
  76. LeBoit PE, Schneider S. Gout presenting as lobular panniculitis. Am J Dermatopathol. 1987;9:334–338
  77. Niemi KM. Panniculitis of the legs with urate crystal deposition. Arch Dermatol. 1977;113:655–656
  78. Strickland RW, Vukelja SJ, Wohlgethan JR, et al. Hemorrhagic subcutaneous bursitis. J Rheumatol. 1991;18:112–114
  79. Macfarlane DG, Dieppe PA. Diuretic-induced gout in elderly women. Br J Rheumatol. 1985;24:155–157
  80. Lally EV, Zimmermann B, Ho G, et al. Urate-mediated inflammation in nodal osteoarthritis: clinical and roentgenographic correlations. Arthritis Rheum. 1989;32:86–90
  81. Chopra KF, Schneiderman P, Grossman ME. Finger pad tophi. Cutis. 1999;64:233–236
  82. Holland NW, Jost D, Beutler A, et al. Finger pad tophi in gout. J Rheumatol. 1996;23:690–692
  83. Eng AM, Schmidt K, Bansal V. Finger pad deposits. Gout. Arch Dermatol. 1994;130:1435–1438
  84. Shmerling RH, Stern SH, Gravallese EM, et al. Tophaceous deposition in the finger pads without gouty arthritis. Arch Intern Med. 1988;148:1830–1832
  85. Fam AG, Assaad D. Intradermal urate tophi. J Rheumatol. 1997;24:1126–1131
  86. Usuki K, Yamashita M, Kanzaki T. A case of pseudogout. J Dermatol. 2000;27:284–287
  87. Dacko A, Hardick K, McCormack P, et al. Gouty tophi: a squamous cell carcinoma mimicker?. Dermatol Surg. 2002;28:636–638
  88. Walsh NM, Murray S, D'Intino Y. Eruptive xanthomata with urate-like crystals. J Cutan Pathol. 1994;21:350–355
  89. Walsh JS, Fairley JA. Calcifying disorders of the skin. J Am Acad Dermatol. 1995;33:693–706[quiz 7-10]
  90. Tiliakos N, Morales AR, Wilson CH. Use of ultrasound in identifying tophaceous versus rheumatoid nodules. Arthritis Rheum. 1982;25:478–479
  91. Reginato AJ, Ferreiro J, Seoane L, Barbazan Alvarez C, et al. Arthropathy and cutaneous calcinosis in hemodialysis oxalosis. Arthritis Rheum. 1986;29:1387–1396
  92. Fam AG. Cholesterol crystals in gouty bursitis. J Rheumatol. 2001;28:1928–1929
  93. Fam AG. Calcium pyrophosphate crystal deposition disease and other crystal deposition diseases. Curr Opin Rheumatol. 1992;4:574–582
  94. Fam AG. Subcutaneous cholesterol crystal deposition and tophus formation. Arthritis Rheum. 1989;32:1190–1191
  95. Fam AG, Sugai M, Gertner E, et al. Cholesterol “tophus”. Arthritis Rheum. 1983;26:1525–1528
  96. Balbir-Gurman A, Nahir AM, Braun-Moscovici Y, et al. Sonographic features of a tophaceous nodule. Isr Med Assoc J. 2005;7:746–747
  97. Batalov AZ, Kuzmanova SI, Penev DP. Ultrasonographic evaluation of knee joint cartilage in rheumatoid arthritis patients. Folia Med (Plovdiv). 2000;42:23–26
  98. Filippucci E, Ciapetti A, Grassi W. Sonographic monitoring of gout. Reumatismo. 2003;55:184–186
  99. Nalbant S, Corominas H, Hsu B, et al. Ultrasonography for assessment of subcutaneous nodules. J Rheumatol. 2003;30:1191–1195
  100. O'Leary ST, Goldberg JA, Walsh WR. Tophaceous gout of the rotator cuff: a case report. J Shoulder Elbow Surg. 2003;12:200–201
  101. Wakefield RJ, Emery P, Pease C. Gout related upper limb cellulitis: an ultrasound study. J Rheumatol. 2003;30:417–419
  102. Backhaus M, Schmidt WA, Mellerowicz H, et al. Technical aspects and value of arthrosonography in rheumatologic diagnosis. 4: Ultrasound of the elbow. Z Rheumatol. 2002;61:415–425
  103. Lyburn ID, Torreggiani WC, Harris AC, et al. Tophaceous podagra: ultrasound diagnosis. Hosp Med. 2002;63:48–49
  104. Mahmud T, Basu D, Dyson PH. Crystal arthropathy of the lumbar spine: a series of six cases and a review of the literature. J Bone Joint Surg Br. 2005;87:513–517
  105. Chen CH, Chen CK, Yeh LR, et al. Intra-abdominal gout mimicking pelvic abscess. Skeletal Radiol. 2005;34:229–233
  106. Gentili A, Sorenson S, Masih S. MR imaging of soft-tissue masses of the foot. Semin Musculoskelet Radiol. 2002;6:141–152
  107. Oostveen JC, van de Laar MA. Magnetic resonance imaging in rheumatic disorders of the spine and sacroiliac joints. Semin Arthritis Rheum. 2000;30:52–69
  108. Seidl G, Ullrich R, Trattnig S, et al. MR imaging in gout. Radiologe. 1996;36:632–636
  109. Popp JD, Bidgood WD, Edwards NL. Magnetic resonance imaging of tophaceous gout in the hands and wrists. Semin Arthritis Rheum. 1996;25:282–289
  110. Jelinek J, Pearl AB, Kominsky SJ, et al. Magnetic resonance imaging of the foot. Rheumatologic disorders mimicking osteomyelitis. J Am Podiatr Med Assoc. 1996;86:228–231
  111. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs. 2004;64:2399–2416
  112. Schlesinger N, Schumacher HR. Gout: can management be improved?. Curr Opin Rheumatol. 2001;13:240–244
  113. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751–1756
  114. Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging. 1998;13:229–243
  115. Onder G, Pellicciotti F, Gambassi G, et al. NSAID-related psychiatric adverse events: who is at risk?. Drugs. 2004;64:2619–2627
  116. Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med. 1982;96:317–320
  117. Pham K, Hirschberg R. Global safety of coxibs and NSAIDs. Curr Top Med Chem. 2005;5:465–473
  118. Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol. 2005;45:742–750
  119. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247–1255
  120. Full online prescribing information for Celebrex© (Pfizer Pharmaceuticals): http://www.pfizer.com/pfizer/download/uspi_celebrex.pdf.2005
  121. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med. 2005;165:978–984
  122. Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med. 1987;316:1562–1568
  123. Moreland LW. Febuxostat—treatment for hyperuricemia and gout?. N Engl J Med. 2005;353:2505–2507
  124. Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450–2461
  125. Wurzner G, Gerster JC, Chiolero A, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens. 2001;19:1855–1860
  126. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol. 1979;1:365–374
  127. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, et al. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis. 2001;60:981–983
  128. Ferraz MB. An evidence based appraisal of the management of nontophaceous interval gout. J Rheumatol. 1995;22:1618–1619
  129. Fam AG, Dunne SM, Iazzetta J, et al. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum. 2001;44:231–238
  130. Bouloc A, Reygagne P, Lecoz P, et al. Perforating foot ulceration with allopurinol therapy. Clin Exp Dermatol. 1996;21:351–352
  131. Emmerson BT. The management of gout. N Engl J Med. 1996;334:445–451
  132. Schumacher HR. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs. 2005;14:893–903

PII: S0738-081X(06)00104-0

doi: 10.1016/j.clindermatol.2006.07.015

Clinics in Dermatology
Volume 24, Issue 6 , Pages 498-508 , November 2006

Article Tools

* Image Usage & Resolution